Researchers began to study and large on the set of a new vaccine that is used against Kttaam more common types of lung cancer.
Will participate more than 1,300 patients around the world in the study that will lay the so-called serum (Stmiuvaks), which increases the survival of many patients with lung cancer.
Lung cancer is the most common types of cancer and causes a large proportion of deaths around the world.
The serum works to stimulate the body's immune cells to attack cancer cells.
The study aimed at the type of lung cancer cells is not known, which represents the big four to five times of the cases.
Currently patients receive a combination of chemotherapy and radiation.
The treatment will be half of the patients physiotherapy in addition to the new vaccination with the other half will receive treatment only, without vaccination, and scientists studying the impact of vaccination in patients.
The scientists from the British Institute for Cancer Research have developed the new vaccine was given Takhid the production of this serum to Bayomira Canadian company.
Says Chief Executive Officer of Technology Cancer Research Institute, Dr. Keith Pellnda: "Vaccinations are a new approach and promising to provide new therapeutic options for the main types of cancer."
Other researchers are working on to look at the effectiveness of vaccination with the same other types of cancer.
It works by stimulating the vaccine cells in the body's immune system to attack the compound named (MUC-1), which resides on the surface of cancer cells.
Once this happens you will be able cells of the immune system to destroy cancer cells and leave it as is.
It was clear from the study of small and he has responded with 171 patients that the vaccine helps patients in their struggle against the disease.
And follow-up of patients after treatment found that those who did not receive vaccination lived for 13 months while he lived, who had been vaccinated 30 months or more.
But if the case matches the results may be the production of serum for use in cancer patients.
Says Chief Executive of the Institute of Cancer Research UK: "to translate these results in the interest of cancer patients is the focus of our work and hope that these projects lead to the development of new drugs in question."
Will participate more than 1,300 patients around the world in the study that will lay the so-called serum (Stmiuvaks), which increases the survival of many patients with lung cancer.
Lung cancer is the most common types of cancer and causes a large proportion of deaths around the world.
The serum works to stimulate the body's immune cells to attack cancer cells.
The study aimed at the type of lung cancer cells is not known, which represents the big four to five times of the cases.
Currently patients receive a combination of chemotherapy and radiation.
The treatment will be half of the patients physiotherapy in addition to the new vaccination with the other half will receive treatment only, without vaccination, and scientists studying the impact of vaccination in patients.
The scientists from the British Institute for Cancer Research have developed the new vaccine was given Takhid the production of this serum to Bayomira Canadian company.
Says Chief Executive Officer of Technology Cancer Research Institute, Dr. Keith Pellnda: "Vaccinations are a new approach and promising to provide new therapeutic options for the main types of cancer."
Other researchers are working on to look at the effectiveness of vaccination with the same other types of cancer.
It works by stimulating the vaccine cells in the body's immune system to attack the compound named (MUC-1), which resides on the surface of cancer cells.
Once this happens you will be able cells of the immune system to destroy cancer cells and leave it as is.
It was clear from the study of small and he has responded with 171 patients that the vaccine helps patients in their struggle against the disease.
And follow-up of patients after treatment found that those who did not receive vaccination lived for 13 months while he lived, who had been vaccinated 30 months or more.
But if the case matches the results may be the production of serum for use in cancer patients.
Says Chief Executive of the Institute of Cancer Research UK: "to translate these results in the interest of cancer patients is the focus of our work and hope that these projects lead to the development of new drugs in question."
ليست هناك تعليقات:
إرسال تعليق